Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28847999 | 0.89 | SLC6A2 (0.37) | SLC6A4HTR2ASLC6A2SLC6A3HTR2B | |
| SCHEMBL28444287 | 0.84 | SLC6A2 (0.35) | SLC6A4HTR2ASLC6A2SLC6A3HTR2B | |
| SCHEMBL4682678 | 0.82 | ADRB2 (0.36) | SLC6A4HTR2ASLC6A2SLC6A3HTR2B | |
| SCHEMBL7294176 | 0.82 | HTR2A (0.34) | SLC6A4HTR2ASLC6A2SLC6A3HTR2B | |
| SCHEMBL27987174 | 0.81 | SLC6A2 (0.39) | SLC6A4HTR2ASLC6A2SLC6A3HTR2B | |
| SCHEMBL8059750 | 0.81 | SLC6A2 (0.39) | SLC6A4HTR2ASLC6A2SLC6A3HTR2B | |
| SCHEMBL22081089 | 0.80 | SLC6A2 (0.41) | SLC6A4HTR2ASLC6A2SLC6A3HTR2B | |
| SCHEMBL11802556 | 0.79 | HTR2A (0.40) | SLC6A4HTR2ASLC6A2SLC6A3HTR2B | |
| SCHEMBL9057558 | 0.77 | SLC6A2 (0.44) | SLC6A4HTR2ASLC6A2SLC6A3HTR2B | |
| SCHEMBL9973633 | 0.77 | SLC6A2 (0.44) | SLC6A4HTR2ASLC6A2SLC6A3HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464623-B1 | THE RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2020-11-04 | — | — | EP | disclosed |
| US-8779198-B2 | Ring opening of lactones and lactams | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-1689702-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-20120165555-A1 | RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-8084485-B2 | 6-(aminoalkyl)indazoles | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8058307-B2 | Alcanoic acid amides substituted by saturated O-heterocycles | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20110144197-A1 | ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES | SPEEDEL EXPERIMENTA AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-7919529-B2 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | NOVARTIS AG (CH) | 2011-04-05 | — | — | US | disclosed |
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005051895-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | REN, AGTR1, AGTR2 | SLC6A4 681/4885HTR2A 1966/4885SLC6A2 281/4885 |
| US-20110144197-A1 | ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES | REN, AGTR1, ACE | SLC6A4 2264/4885HTR2A 2271/4885SLC6A2 919/4885 |
| US-20120165555-A1 | RING OPENING OF LACTONES AND LACTAMS | LSS, APH1A, OTUB1 | SLC6A4 4881/4885HTR2A 4820/4885SLC6A2 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.